Biosketch Francesc Bosch

Francesc Bosch
fbosch@vhio.net
Lloc actual
  • 2016 – actualitat: Cap de grup, Grup d’Hematologia Experimental del VHIO
  • 10/2010 – actualitat: Professor del Departament de Medicina de la Universitat Autònoma de Barcelona, Espanya
  • 09/2009 – actualitat: Cap del Departament d’Hematologia de l’Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Espanya
Formació acadèmica
  • 09/1992 – 09/1993: Universitat Autònoma de Barcelona, Espanya
    Anàlisi multivariable en ciències de la salut
  • 09/1993 – 09/1994: Universitat Autònoma de Barcelona, Espanya
    Fonaments del disseny i l’estadística (mèdics)
  • 09/1982 – 10/1988: Universitat de Barcelona, Espanya
    Llicenciatura en Medicina i Postgrau en Cirurgia
  • 10/1988 – 12/1992: Universitat de Barcelona, Espanya
    Certificat en Hematologia del Consell Espanyol
  • 07/1998:  Universitat de Barcelona, Espanya
    Tesi doctoral: «El gen de la ciclina D1 en els trastorns limfoproliferatius crònics»
    Premi Extraordinari de Doctorat
Àrees de recerca
  • Estudis biològics i clínics en neoplàsies hematològiques.
Premis i beques

Premis

  • 07/1998: Premi Extraordinari de Doctorat
  • 1996: Premi per a Joves Investigadors, París. Societat Europea d’Hematologia
  • 1994: Premi per a Joves Investigadors. Societat Catalana d’Hematologia
  • 2018: Premi Best in Class (BiC) a la millor unitat de CLL.
  • 2014: Premi a l’Excel·lència Professional. Col·legi Oficial de Metges de Barcelona

Honors

  • 07/2009: Coordinadora del Grup Espanyol de CLL
  • 2007: Principal organitzadora del Grup de Joves Investigadors sobre LLC
  • 1996: Membre del Projecte Europeu per al Limfoma de Cèl·lules del Mantell
  • 1996: Membre fundadora del Grup d’Estudi dels Limfomes a Catalunya i les Balears (GELCAB)

Beques:

  • 01/1998 – 12/2000: Institut de Genètica del Càncer, Universitat de Columbia, Nova York, EUA. Investigadora postdoctoral
  • 09/2017 – 09/2018: Institut de Genètica del Càncer, Universitat de Columbia, Nova York, EUA. Investigadora postdoctoral
Projectes
  • Project title: Exploración y prueba de concepto de la eficacia del tratamiento combinado con Ory-1001 en indicaciones oncológicas (COMBO-EPoC).
    Duration: 01/01/2018 – 31/03/2021.
    Funding entity: MINECO-RETOS
    PI: Francesc Bosch.
  • Project title: Uso de linfocitos T específicos third partycontra antígenos virales, procedentes de un registro de donantes voluntarios, para el tratamiento de infecciones por CMV, VEB y adenovirus.
    Duration: 01/01/2017 – 30/06/2021.
    Funding entity: FIS-ISCIII.
    PI: Pere Barba.
  • Project title: Estudio funcional del sistema inmune (SI) en síndromes mielodisplásicos (SMD) según el perfil mutacional. Influencia de las alteraciones evolutivas del SI en la progresión del SMD.
    Duration: 01/01/2018 – 01/07/2021.
    Funding entity: FIS-ISCIII.
    PI: David Valcarcel
  • Project title: Patogénesis y nuevas dianas moleculares en sindromes linfoproliferativos.
    Duration: 01/12/2013 – 31/12/2021.
    Funding entity: MINECO-RyC (MINECO Ramón y Cajal).
    PI: Marta Crespo.
  • Project title: Papel de la vigilancia y evasión inmune en la fisiopatología y inmunoterapia de los linfomas del sistema nervioso central.
    Duration: 01/01/2018 – 01/01/2022.
    Funding entity: FIS-ISCIII.
    PI: Marta Crespo.
  • Project title: Optimización del uso de inhibidores de checkpoint en pacientes con neoplasias linfoides que reciben un trasplante alogénico de progenitores hematopoyético.
    Duration: 01/08/2019 – 01/03/2022.
    Funding entity: Fundación Científica de la Asociación Española Contra el Cáncer.
    PI: Pere Barba.
  • Project title: EVALUACIÓN DE IMPACTO SOBRE LA CALIDAD DE VIDA EN PACIENTES CON HEMOFILIA B EN PROFILAXIS TRAS EL CAMBIO A FIX EHL EN COMPARACIÓN CON TRATAMIENTO PREVIO.
    Duration: 01/09/2020 – 31/03/2022.
    Funding entity: Swedish Orphan Biovitrum, S. L.
    PI: Olga Benitez.
  • Project title: Inhibición de la proteína quinasa ZAP-70 como terapia dirigida en linfomas T periféricos.
    Duration: 13/03/2019 – 31/03/2022
    Funding entity: ROCHE FARMA S.A.
    PI: Marta Crespo.
  • Project title: Macrophage-mediated immunotherapy optimization in lymphomas affecting the central nervous system.
    Duration: 01/11/2018 – 31/10/2022.
    Funding entity: Fundación Científica de la Asociación Española Contra el Cáncer.
    PI: Marta Crespo.
  • Project title: Programa de colaboración con Diagnostic Grifols para verificación y validación de reactivos e instrumentación de diagnóstico clínico in vitro mediante la cesión de muestras de plasma citratado sobrante de la rutina asistencial.
    Duration: 01/06/2017 – 31/12/2022.
    Diagnostic Grifols, S.A.
    PI: Francesc Bosch.
  • Project title: Convenio de Colaboración en el Proyecto “Enlace”.
    Duration: 01/07/2017 – 31/12/2022.
    Funding entity: CELGENE, SL.
    PI: Francesc Bosch.
  • Project title: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, verus Unmanipulated Umbilical Cord Blood for Patients with Hematoligical Malignancies.
    Duration: 04/01/2018 – 31/12/2022.
    Funding entity: Gamida Cell Ltd.
    PI: David Valcarcel.
  • Project title: Predicción de la respuesta a lusparceptept en los síndromes mielodiplásicos: análisis de la diferenciación eritroide terminal mediante un sist. ex vivo y RNA seq.
    Duration: 01/03/2018 – 31/12/2022.
    Funding entity: Fundación Española de Hematología y Hemoterapía.
    PI: Francesc Bosch.
  • Project title: Evaluation of the combination between the PI3K delta inhibitor GS-1101/Idelalisib and the BET inhibitor GS-626510 in preclinical models of diffuse large B cell lymphoma.
    Duration: 16/03/2018 – 31/12/2022.
    Funding entity: INSTITUT D’INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (IDIBAPS).
    PI: Francesc Bosch.
  • Project title: Evaluation of the “U2” drug comobo in association with anti-PD-L1 antibody, BET inhibitor TG-1601, BTK inhibitor RG-1701, in preclinical models of B-cell non-Hodgkin lymphoma (B-NHL).
    Duration: 28/05/2018 – 31/12/2022.
    Funding entity: TG Therapeutics, INC.
    PI: Francesc Bosch.
  • Project title: Prevención biomecánica de la Salud Articular en pacientes con Hemofilia A y B.
    Duration: 03/10/2018 – 31/12/2022.
    Funding entity: Novo Nordisk Pharma, S.A.
    PI: Amparo Santamaria.
  • Project title: Prevención biomecánica de la salud articular en pacientes con hemofilia A y B.
    Duration: 18/10/2018 – 31/12/2022.
    Funding entity: PFIZER S.L.U.
    PI: Amparo Santamaria.
  • Project title: Inhibición de la proteína quinasa ZAP-70 como terapia dirigida en linfomas T periféricos.
    Duration: 01/01/2019 – 31/12/2022.
    Funding entity: FIS-ISCIII.
    PI: Pau Abrisqueta.
  • Project title: Prevención Biomecánica de la Salud Articular de EEII en pacientes con Coagulopatías Congénitas.
    Duration: 03/12/2018 – 31/12/2022.
    Funding entity: Swedish Orphan Biovitrum, S. L.
    PI: Amparo Santamaria.
  • Project title: European Paediatric Network for Haemophilia Management and the PedNet Haemophilia Registry.
    Duration: 20/11/2018 – 31/12/2022.
    Funding entity: PedNet Haemophilia Research Foundation.
    PI: Amparo Santamaria.
  • Project title: Proyecto de colaboración con diagnostico Grifols para la verificación y validez de reactivos e instrumentación de diagnóstico in vitro mediante la cesión de muestras de plasma citrado sobrante de la rutina asistencial.
    Duration: 30/07/2019 – 31/12/2022.
    Funding entity: Diagnostic Grifols, S.A.
    PI: Francesc Bosch.
  • Project title: Análisis de MRD en muestras del ensayo ALICE.
    Duration: 11/11/2019 – 31/12/2022.
    Funding entity: ORYZON GENOMICS, S.A.
    PI: Francesc Bosch.
  • Project title: First in man study with MEN1112, a CD157 targeted monoclonal antibody, in relapsed or refractory Acute Myeloid Leukemia (ARMY).
    Duration: 06/05/2020 – 31/12/2022.
    Funding entity: Labcorp Clinical Development Limited.
    PI: Francesc Bosch.
  • Project title: Edoxaban Treatment in routiNe c!inical prActice for patients with Atrial Fibril!ation in Europe {ETNA-AF-Europef).
    Duration: 31/07/2020 – 31/12/2022.
    Funding entity: DAIICHI-SANKYO ESPAÑA S.A.
    PI: Francesc Bosch.
  • Project title: Seguimiento por telemonitorización de los pacientes con hemofilia a través de aplicación farmacocinética.
    Duration: 27/10/2020 – 31/12/2022.
    Funding entity: Swedish Orphan Biovitrum, S. L.
    PI: Olga Benitez.
  • Project title: Hallazgos epidemiológicos y moleculares en la leucemia linfocítica crónica: estudio observacional retrospectivo de la red colaborativa nacional española RED53 / IGHV (Estudio EPICELL).
    Duration: 21/12/2020 – 31/12/2022.
    Funding entity: JANSSEN CILAG S.A.
    PI: Francesc Bosch.
  • Project title: Natural History and Treatment Outcomes of Congenital and Immune Thrombotic Thrombocytopenic Purpura: a Retrospective Chart Review Study.
    Duration: 04/10/2021 – 31/12/2022.
    Funding entity: HCD Economics Ltd.
    PI: David Valcarcel.
  • Project title: Ánalisis de genes implicados en cáncer hematológico de origen mieloide.
    Duration: 17/12/2015 – 31/12/2022.
    Funding entity: CELGENE, S.L.U.
    PI: Francesc Bosch.
  • Project title: Medicina de precisión aplicada al cáncer hematológica: Plataforma de secuenciación masiva para estudio de biomarcadores de cáncer hematológico.
    Duration: 01/01/2016 – 31/12/2022
    Funding entity: ROCHE FARMA, S.A.
    PI: Francesc Bosch.
  • Project title: Secuenciación de TP53 en Leucemia Linfática Crónica.
    Duration: 01/04/2016 – 31/12/2022.
    Funding entity: JANSSEN CILAG S.A.
    PI: Francesc Bosch.
  • Project title: Nuevas opciones terapéuticas para el tratamiento de los linfomas cerebrales primarios: terapias dirigidas hacia vías de señalización desreguladas usando modelos in vivo.
    Duration: 07/07/2017 – 31/12/2022.
    Funding entity: ROCHE FARMA S.A.
    PI: Francesc Bosch.
  • Project title: Immunological effects of TAK-659 for treating hematological malignancies including chronic lymphocytic leukemia.
    Duration: 23/10/2017 – 31/12/2022.
    Funding entity: MILLENNIUM PHARMACEUTICALS, Inc.
    PI: Francesc Bosch.
  • Project title: Testing of ARQ 531 in CNS lymphoma models.
    Duration: 21/05/2018 – 31/12/2022.
    Funding entity: ArQule.
    PI: Marta Crespo.
  • Project title: Optimization of immnunotherapy design in CD20+ lumphomas and in AML by developing humanized mice models and characterizing malignant cell and inmune system crosstalk.
    Duration: 07/11/2018 – 31/12/2022.
    Funding entity: F. Hoffmann-La Roche Ltd.
    PI: Francesc Bosch.
  • Project title: Understanding the tumor immune microenvironment in diffuse large B-cell lymphoma for the development of immunotherapeutic strategies that target each individual’s immune biology-GILEAD.
    Duration: 19/02/2019 – 31/12/2022.
    Funding entity: GILEAD SCIENCES S.L.
    PI: Francesc Bosch.
  • Project title: Characterization of EO2463 specific T lymphocytes/ T cell clones in patients with Chronic Lymphocytic Leukemia.
    Duration: 11/02/2021 – 31/12/2022.
    Funding entity: Enterome SA.
    PI: Marta Crespo.
  • Project title: Healthcare Alliance for Resourceful Medicines Offensive aganist Neoplasms in Hematology.
    Funding entity: INNOVATIVE MEDICINES INITIATIVE (IMI).
    PIs: Francesc Bosch, Marta Crespo.
  • Project title: Estudi i implicacions translacionals de l’evasió del sistema immunitari en la leucèmia limfàtica crónica.
    Duration: 01/06/2020 – 12/07/2023.
    Funding entity: MARATÓ TV3.
    PI: Francesc Bosch.
  • Project title: Red cooperativa franco-española para el análisis de proteinopatías y el desarrollo de terapias individualizadas en cánceres hematológicos
    Duration: 01/06/2019 – 31/12/2023.
    PI: David Valcarcel.
Publicacions científiques més rellevants
  • Jiménez I, Tazón-Vega B, Abrisqueta P, Nieto JC, Bobillo S, Palacio-García C, Carabia J, Valdés-Mas R, Munuera M, Puigdefàbregas L, Parra G, Esteve-Codina A, Franco-Jarava C, Iacoboni G, Terol MJ, García-Marco JA, Crespo M, Bosch F. Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Biomark Res. 2021 May 20;9(1):37.
  • Jiménez M, Roldán E, Fernández-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Gironella M, Fox L, Orti G, Barba P, Pumarola T, Cabirta A, Catalá E, Valentín M, Marín-Niebla A, Orfao A, González M, Campins M, Ruiz-Camps I, Valcárcel D, Bosch F, Hernández M, Crespo M, Esperalba J, Abrisqueta P. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774-784. Blood Adv. First Edition 29 November 2021 (online prepublication).
  • Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. Epub 2021 Dec 14.
  • Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. Epub 2021 Dec 14.
  • Olga Salamero, Pau Montesinos, Christophe Willekens, José Antonio Pérez-Simón, Arnaud Pigneux, Christian Récher, Rakesh Popat, Cecilia Carpio, César Molinero, Cristina Mascaró, Joaquim Vila, M Isabel Arévalo, Tamara Maes, Carlos Buesa, Francesc Bosch, Tim C P Somervaille. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology 2020 Dec 20; 38(36):4260-4273
  • Abrisqueta P, Bosch F. Venetoclax-obinutuzumab: harnessing complexity. Blood 2020 Mar 12; 135(11):788-789
  • Jiménez I, Carabia J, Bobillo S, Palacio C, Abrisqueta P, Pagès C, Nieto JC, Castellví J, Martínez-Ricarte F, Escoda L, Perla C, Céspedes Torrez DH, Boix J, Purroy N, Puigdefàbregas L, Seoane J, Bosch F, Crespo M. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. J Neurooncol. 2020 Aug;149(1):13-25.
  • Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellvi J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, Seoane, J. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. Epub ahead of print.
  • Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, WeiX, Hege K, Trotter MWB, Risueño A, Buchholz TJ, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. 2020 Mar 26;135(13):996-1007.
  • Muntañola A, Villacampa G, Hernández-Rivas JÁ, Alonso R, Mirás F, Osorio S, Baile M, Baltasar P, López Jiménez J, Hernandez-Rodriguez I, Valenciano S, Alfayate A, Gimeno E,Bárez A, Oliveira AC, Riaza R, Romero P, Delgado J, Yáñez L, Zabalza A, Torres A, Gómez-Roncero MI, Crespo M, Córdoba R, Mateos-Mazón JJ, Pérez S, Andreu R, Labrador J, Ruiz ME, Velasquez CA, Terol MJ, Santiago R, Vidal MJ, Campoy García F, Villalón L, Muiña BS, Soler JA, Seri C, Sánchez MJ, Cuesta A, Ramos R, Sánchez- Montalvá A, Ruiz-Camps I, González M, Abrisqueta P, Bosch F; of the GELLC (Grupo Español de Leucemia Linfática Crónica). Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Exp Hematol Oncol. 2020 Dec 18;9(1):37.
  • Bosch F, Dalla-Favera R. Chronic Lymphocytic Leukaemia: From Genetics to Treatment. Nat Rev Clin Oncol. 16 (11), 684-701, Nov 2019.
  • Bosch F, Cantin G, Cortelezzi A, Knauf W, Tiab M, Turgut M, Zaritskey A, Merot J-L, Tausch E, Trunzer K, Robson S, Gresko E, Böttcher S, Foà R, Stilgenbauer S, Leblond V. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia, 34 (2), 441-450. 2019.
  • Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé BS, López-Guillermo A, Campo E, Monserrat E. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75.
  • Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84.
  • Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Somasekar S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Jan 22;18(2):221-3
  • Purroy N; Abrisqueta P; Carabia J; Carpio C; Calpe E; Palacio C; Castellví J; Crespo M; Bosch F. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 28 – (10), pp. 1993 – 2004.
Totes les publicacions
  • Noelia Purroy; Júlia Carabia; Pau Abrisqueta; Leire Egia; Meritxell Aguiló; Cecilia Carpio; Carles Palacio; Marta Crespo; Francesc Bosch. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget. 2017 Jan 3;8(1):742-756
  • Orti G; Barba P; Fox L; Salamero O; Bosch F; Valcarcel D. Donor Lymphocyte Infusions in AML and MDS:enhancing the Graft-versus-Leukemia effect. Experimental Hematology. 24/12/2016.  [Epub ahead of print]
  • Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; tamatopoulos K; Espinet B. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget. 2016 Dec 6;7(49):80916-80924
  • Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic LymphocyticLeukemia. Advanced Therapies. 33(10), pp. 1814 – 1830. 03/10/2016.
  • González-Gascón Y Marín I; Hernández-Sánchez M; Rodríguez-Vicente AE; Sanzo C; Aventín A; Puiggros A; Collado R; Heras C; Muñoz C; Delgado J; Ortega M; González MT; Marugán I; de la Fuente I; Recio I; Bosch F; Espinet B; González M; Hernández-Rivas JM; Hernández JÁ;; On behalf of Grupo Español de Leucemia Linfática Crónica (GELLC); Grupo Cooperativo Español de Citogenética Hematológica (GCECGH). A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematol Oncol. 2016 Jun;34(2):84-92
  • Bär C; Povedano JM; Serrano R; Benitez-Buelga C; Popkes M; Formentini I; Bobadilla M; Bosch F; Blasco MA. Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. Blood. 127 – 14, pp. 1770 – 1779. 07/04/2016.
  • Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O’Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; , Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E. A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An European research initiative on CLL (ERIC) study. Leukemia. 2016 Apr;30(4):929-36.
  • Pons V; Olivera P; García-Consuegra R,; López-Andreoni L; Martín-Begué N; García A, Hidalgo J,; Bosch F; Santamaría A. Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. J Thromb Thrombolysis. 2016 Apr;41(3):544-7
  • Hernández JÁ; Hernández-Sánchez M; Rodríguez-Vicente AE; Grossmann V; Collado R; Heras C; Puiggros A; Martín AÁ; Puig N; Benito R; Robledo C; Delgado J; González T; Queizán JA; Galende J; de la Fuente I; Martín-Núñez G; Alonso JM; Abrisqueta P; Luño E; Marugán I; González-Gascón I; Bosch F; Kohlmann A; González M; Espinet B; Hernández-Rivas JM. A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. PLoS One. 2015 Dec 2;10(11):e0143073.
  • Riveiro-Barciela M; Artaza G; Abrisqueta P; Bosch F; Buti M. Importance of hepatitis B virus screening in hematological patients. Gastroenterol Hepatol. 2015 Nov;38(9):563-4
  • Purroy N; Abrisqueta P; Carabia J; Carpio C; Palacio C; Bosch F; Crespo M. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2015 Apr 10;6(10):7632-43.
  • Purroy N; Abrisqueta P; Carabia J; Carpio C; Calpe E; Palacio C; Castellví J; Crespo M; Bosch F. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 28 – (10), pp. 1993 – 2004.
  • Maria Joao Baptista; Eva Calpe; Eva Fernández; Lluis Colomo; Teresa Marta Cardesa-Salzmann; Pau Abrisqueta; Francesc Bosch; Marta Crespo. Analysis of the IGHV region in Burkitt’s lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis. Leuk Res. 2014 Apr;38(4):509-15
  • Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72
  • Abrisqueta P; Villamor M; Terol MJ; González- Barca E; Ferrà C; Abella E; Delgado J; Garcia-Marco JA; Gonzalez Y; CarbonellF; Monzo E; Jarque I; Muntañola A; Constants M; Escoda L; Calvo X; Bobillo S; Montoro JB; Montserrat E; Bosch F. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013 Dec 5;122(24):3951-9.05/12/2013.
  • Calpe E; Purroy N; Carpio C; Abrisqueta P; Carabia J; Palacio C; Castellví J; Crespo M; Bosch F.ZAP-70 Promotes the Infiltration of Malignant B-Lymphocytes into the Bone Marrow by Enhancing Signaling and Migration after CXCR4 Stimulation. PLoS One. 2013 Dec 3;8(12):e81221.
  • Puiggros A; DelgadoJ; Rodriguez- Vicente A; Collado R; Aventín A; Luño E; Luño E; Grau J; Hernandez JÁ; Marugán I; Ardanaz M; González T; Valiente A; Osma M; Calasanz MJ; Sanzo C; Carrió A; Ortega M; Santacruz R; Abrisqueta P; Abella E; Bosch F; Carbonell F; Solé F; Hernández JM; Espinet B. Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. Br J Haematol. 2013 Oct;163(1):47-54
  • Mora D; Barba P; Castillo N; Aizpurua M; Rosellé E; Bosch F; Valcárcel D. Primary gastrointestinal aspergillosis 6 months after allogeneic hematopoietic cell transplantation: a case report. Transpl Infect Dis. 2013 Jun;15(3):E107-10
  • Villamor N; Conde L; Martínez-Trillos A; Cazorla M; Navarro A; Beà S; López C; Colomer D; Pinyol M; Aymerich, M; Rozman M; Abrisqueta P; Baumann T; Delgado J; Giné E; González-Díaz M; Hernández JM; Colado E; Payer AR; Rayon C; Navarro B; José Terol M; Bosch F; Quesada V; Puente XS; López-Otín C; Jares P; Pereira A; Campo E; López-Guillermo A. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013 Abr; 27(5): 1100 – 1106.
  • Baptista MJ, Muntanola A, Calpe E, Abrisqueta P, Salamero O, Fernandez E, Codony C, Gine E, Kalko SG, Crespo M, Bosch F. Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clin Cancer Res. 2012 Sep;18(21):5924-33.
  • Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymph. 2012 Mar;53(3):417-23.
  • Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Somasekar S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Jan 22;18(2):221-3
  • Calpe E, Codony C, Baptista MJ, Abrisqueta P, Del Carpio C, Purroy N, Bosch F, Crespo M. ZAP-70 enhances migration of malignant B lymphocytes towards CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 2011 Oct 20; 111(16): 4401-10- 2011.
  • Antón A, López-Iglesias AA, Tórtola T, Ruiz-Camps I, Abrisqueta P, Llopart L, Marcos MÁ, Martínez MJ, Tudó G, Bosch F, Pahissa A, de Anta MT, Pumarola T. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. Diagn Microbiol Infect Dis. 2010 Nov;68(3):214-9.
  • M Hallek*, K Fischer*, G Fingerle-Rowson, A M Fink, R Busch, J Mayer, M Hensel, G Hopfi nger, G Hess, U von Grünhagen, M Bergmann, J Catalano, P L Zinzani, F Caligaris-Cappio, J F Seymour, A Berrebi, U Jäger, B Cazin, M Trneny, A Westermann, C M Wendtner, B F Eichhorst, P Staib, A Bühler, D Winkler, T Zenz, S Böttcher, M Ritgen, M Mendila, M Kneba, H Döhner, S Stilgenbauer, International Group of investigators; German Chronic Lymphocityc Study Group, Collaborators: Hillmen P, Dighiero G, Bosch F, Brugiatelli M, Pigeot I. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74.
  • Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntañola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010 Sep; 95(9):1526-33.
  • Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E, Bosch F, Campo E, Montserrat E, López-Guillermo A. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.  Leuk Lymph. 2010 Jul;51(7):1225-32
  • Fernández de Larrea C, Martínez C, Gaya A, López-Guillermo A, Rovira M,Fernández-Avilés F, Lozano M, Bosch F, Esteve J, Nomdedeu B, Montserrat E, Carreras E. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Ann Oncol. 2010 Jun;21(6):1211-6.
  • Fernàndez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, Camacho F, Beà S, Hartmann E, Amador V, Hernández L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F, Piris MA, Montserrat E, Ott G, Rosenwald A, López-Guillermo A, Jares P, Serrano S, Campo E. Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Res. 2010 Feb 15; 70(4):1408-18
  • Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84.
  • Abrisqueta P, Pereira A, Rozman C, Aymerich M, Giné E, Moreno C, Muntañola A,Rozman M, Villamor N, Hodgson K, Campo E, Bosch F, Montserrat E. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009 Sep 3;114(10):2044-50
  • Hartmann E, Fernàndez V, Moreno V, Valls J, Hernández L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Müller-Hermelink HK, Ott G, Rosenwald A, Campo E. Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. J Clin Oncol. 2008 Oct 20;26(30):4966-72.
  • Enjuanes A, Benavente Y, Bosch F, Martín-Guerrero I, Colomer D, Pérez-Alvarez S, Reina O, Ardanaz MT, Jares P, García-Orad A, Pujana MA, Montserrat E, de Sanjosé S, Campo E. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res. 2008 Dec 15;68(24):10178-86.
  • Giné E, Crespo M, Muntañola A, Calpe E, Baptista MJ, Villamor N, Montserrat E, Bosch F. Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. Haematologica. 2008 Jan; 93(1):75-82.
  • Fernàndez V, Jares P, Salaverria I, Giné E, Beà S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat E, Campo E. Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica. 2008 Jan; 93(1):132-6.
  • Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008 Jan 1; 14(1):155-61.
  • Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutiérrez G, Mercadal S, Campo E, Rozman C, López-Guillermo A, Montserrat E. Central nervous system involvement in mantle cell lymphoma. Ann Oncol. 2008 Jan;19(1):135-41.
  • Ferrer A, Salaverria I, Bosch F, Villamor N, Rozman M, Bea S, Gine E, Lopez-Guillermo A, Campo E, Montserrat E. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007; 109:2473-80
  • Muntañola A, Bosch F, Arguis P, Arellano-Rodrigo E, Ayuso C, Gine E, Crespo M, Abrisqueta P, Moreno C, Cobo F, Lopez-Guillermo A, Montserrat E. Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic. Leukemia. J Clin Oncol 2007; 25:1576-80
  • Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose JM, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM. Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma. Blood. 2007;109(11):4599-606.
  • Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, Belhoul L, Stella S, Stavroyianni N, Crespo M, Hadzidimitriou A, Sutton L, Bosch F, Laoutaris N, Anagnostopoulos A, Montserrat E, Fassas A, Dighiero G, Caligaris-Cappio F, Merle-Beral H, Ghia P, Davi F. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007; 109:259-70
  • Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006 Oct;17(10):1539-45
  • Bosch F, Muntanola A, Gine E, Carrio A, Villamor N, Moreno C, Crespo M, Montserrat E. Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006; 70:214-7
  • Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A, Campo E, Bosch F, Montserrat E. Clinical significance of minimal residual disease, as assessed by different techniques, after stem-cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563-9
  • Marce S, Balague O, Colomo L, Martinez A, Holler S, Villamor N, Bosch F, Ott G, Rosenwald A, Leoni L, Esteller M, Fraga MF, Montserrat E, Colomer D, Campo E. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res 2006; 12:3754-61.
  • Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How I treat refractory CLL. Blood; 2006; 107:1276-83
  • Crespo M, Villamor N, Gine E, Muntanola A, Colomer D, Marafioti T, Jones M, Camos M, Campo E, Montserrat E, Bosch F. ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res 2006 12:726-34.
  • Plancarte F, Lopez-Guillermo A, Arenillas L, Montoto S, Gine E, Muntanola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E, Montserrat E. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 2006 76:58-63
  • Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, Bosch F, López-Guillermo A, Campo E, Sierra J, Montserrat E. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23(15):3433-8
  • López-Guillermo A, Colomo L, Jiménez L, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beà S, Campo E, Montserrat E. Diffuse large B-cell lymphoma: clinicobiological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005; 23(12):2797-804
  • Hernández L, Beà S, Pinyol M, Ott G, Katzenberger T, Rosenwald A, Bosch F, López-Guillermo A, Delabie J, Colomer D, Montserrat E, Campo E. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 2005; 65: 2199-206.
  • Carreras J, Villamor N, Colomo L, Moreno C, Ramón y Cajal S, Crespo M, Tort F, Bosch F, López-Guillermo A, Colomer D, Montserrat E, Campo E. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005; 205: 507-13.
  • Ferrer A, Marcé S, Bellosillo B, Villamor N, Bosch F, López-Guillermo A, Espinet B, Solé F, Montserrat E, campo E, Colomer D. Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.Oncogene 2004; 23: 8941-9.
  • Montoto S, López-Guillermo A, Altés A, Perea G, Ferrer A, Camós M, Villela L, Bosch F, Esteve J, Cervantes F, Bladé J, Campo E, Sierra J, Montserrat E. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004; 15: 1484-9.
  • Montagut C, Bosch F, Villela L, Rosinol L, Blade J. Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. Leuk Lymph.2004 Aug;45(8):1711-2
  • Tort F, Camacho E, Bosch F, Lee Harris N, Montserrat E, Campo E. Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haematologica 2004; 89:314-9
  • Martínez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D. Nuclear survivin expresion in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004;  164:501-510
  • Bosch F, Villamor N. ZAP-70 expression in chronic lymphocytic leukemia: a new parameter for an old disease. Haematologica 2003; 88:724-26.
  • Perea G, Altés A, Montoto S, López-Guillermo A, Bosch F, Jiménez M, Esteve J, Domingo E, Ribera JM, Pedro C, Martino R, Briones J, Sureda A, Brunet S, Sierra J, Montserrat E. International and Italian prognostic indices in follicular lymphoma. Haematologica 2003; 88: 700-4.
  • Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé BS, López-Guillermo A, Campo E, Monserrat E. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75. (first and corresponding author)
  • Montoto S, Rozman M, Rosinol L, Nadal E, Gine E, Aymerich M, Ferrer A, Esteve J, Bosch F, Lopez-Guillermo A, Blade J, Montserrat E. Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Semin Oncol 2003 Apr;30(2):178-81
  • Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hemerlink KH, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, Feb; 3:185-197.
  • Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84
  • Montoto S, López-Guillermo A, Colomer D, Esteve J, Bosch F, Ferrer A, Villamor N, Moreno C, Campo E, Montserrat E. Incidence and clinical significance of bcl-2/IgH rearrangement in follicular lymphoma. Leuk Lymph 2003; 44: 71-6.
  • Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N, Colomer D, Cobo F, Perales M, Esteve J, Altés A, Besalduch J, Ribera JM, Montserrat, for the GELCAB (Grup per l’Estudi dels Limfomes de Catalunya i Balears). Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976-84.
  • Beà S, López-Guillermo A, Ribas M, Pinyol M, Carrió A, Soler F, Bosch F, Colomer D, Miró R, Montserrat E, Campo E. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large cell lymphoma (Richter’s syndrome). Am J Pathol 2002; 161: 957-68.
  • Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Bosch F, Campo E, Montserrat E, Colomer D. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002; 100: 1810-6.
  • Giné E, Bosch F, Villamor N, Rozman M, Colomer D, López-Guillermo A, Montserrat E. Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia / small lymphocytic lymphoma: a frequent association? Leukemia 2002; 16: 1454-9.
  • Cobo F, Martínez A, Pinyol M, Hernández L, Gómez M, Beà S, Esteve J, Rozman M, Bosch F, López-Guillermo A, Montserrat E, Campo E. Multiple cell cycle regulator alterations in Richter’s transformation of chronic lymphocytic leukemia. Leukemia 2002; 16: 1028-34.
  • Bladé J, Filella X, Montoto S, Bosch F, Rosiñol L, Coca F, Giné E, Nadal E, Aymerich M, Rozman M, Montserrat E. Interleukin 6 and tumor necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. Br J Haematol 2002; 117:387-9
  • Montoto S, López-Guillermo A, Ferrer A, Camós M, Álvarez-Larrán A, Bosch F, Bladé J, Cervantes F, Esteve J, Cobo F, Colomer D, Campo E, Montserrat E. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol 2002; 13: 523-30.
  • Gallart T, Benito C, Reverter JC, Bosch F, Blay M, Tassies D, Vigorito E, Cervera R, Font J, Gomis R, Campo E, Vives J. True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. Br J Haematol 2002;116:875-86
  • Camacho E, Hernández L, Hernández S, Tort F, Bellosillo B, Beà S, Bosch F, Montserrat E, Cardesa A, Fernández PL, Campo E. ATM gene inactivation in mantle cell lymphoma mainly occur by truncating and missense mutations involving the PI-3 kinase domain. Blood 2002 99: 238-244.
  • Boogaerts MA, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani PL, Binet JL, Feremans W, Marcus R, Bosch F, Verhoef G, Klein M. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252-4258
  • Marti RM, Campo E, Bosch F, Palou J, Estrach T. Cutaneous lymphocyte-associated antigen (CLA) expression in a lymphoblastoid mantle cell lymphoma presenting with skin lesions. Comparison with other clinicopathologic presentations of mantle cell lymphoma. J Cutan Pathol 2001 28:256-64.
  • Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, Guccione E, Qu X, Chien M, Murty VV, Gaidano G, Inghirami G, Zhang P, Fischer S, Kalachikov SM, Russo J, Edelman I, Efstratiadis A, Dalla-Favera R. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97:2098-104
  • Villela L, López-Guillermo A, Montoto S, Rives S, Bosch F, Perales M, Ferrer A, Esteve J, Colomo L, Campo E, Montserrat E. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer 2001; 91: 1557-62.
  • Sanz-Vaqué, Ll, Colomer D, Bosch F, López-Guillermo A, Dreyling MH, Ott G, Montserrat E, Campo E. Microsatellite instability analysis in typical and progressed mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Haematologica 2001; 86: 181-6..
  • Migliazza A, Cayanis E, Bosch F, et al. Molecular pathogenesis of B-cell chronic lymphocytic leukemia: analysis of 13q14 chromosomal deletions. Curr Top Microbiol Immunol. 2000;252:275-84.
  • Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Bladé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E. Hybrid chemotherapy C-MOPP/ABV as first line treatment in advanced stage Hodgkin’s disease. Cancer 2000; 88: 2142-8.
  • Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F, Nadal A, Fernandez PL, Palacin A, Montserrat E, Campo E. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin’s lymphomas. Leukemia. 1999; 13:2087-93.
  • Cobo F, Hernández S, Hernández L, Pinyol M, Bosch F, Esteve J, López-Guillermo A, Palacín A, Raffeld M, Montserrat E, Jaffe ES, Campo E. Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma ocurring in an HIV-seronegative patient. J Pathol 1999; 189: 288-93.
  • Terol MJ, López-Guillermo A, Bosch F, Villamor N, Cid MC, Campo E, Montserrat E. Expression of beta-integrin adhesion molecules in non-Hodgkin’s lymphoma: correlation with clinical and evolutive features. J Clin Oncol 1999; 17: 1869-75.
  • Beà S, Ribas M, Hernández JM, Bosch F, Pinyol M, Hernández L, García JL, Flores T, González M, López-Guillermo A, Piris MA, Cardesa A, Montserrat E, Miró R, Campo E. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphomas are associated with blastoid variants. Blood 1999; 93: 4365-74.
  • Geisler C, Hansen MM, Yeap BY, Wiernik P, Binet JL, Chastang C, Dighiero G, Travade P, Jaksic B, Brugiatelli M, Kimby E, Catovsky D, Hamblin T, Richards S, Bosch F, Fontanillas M, Montserrat E, Alison R, Clarke M, Duong H, Elphinstone P, Evans V, Godwin J, Gray R, Greaves E, Hicks C, James S, Mead G, Peto R, Richards S, Wheatley K.  Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials. J Natl Cancer Inst. 1999 May 19;91(10):861-8.
  • Ferrer A, López-Guillermo A, Bosch F, Montoto S, Hernández Boluda JC, Camós M, Miquél R, Campo E, Montserrat E. Linfomas del tejido linfoide asociado a mucosas (MALT) de localización extragástrica: análisis de 14 casos. Med Clin (Barc) 1999; 112: 577-80.
  • Espinet B, Sole F, Woessner S, Bosch F, Florensa L, Campo E, Costa D,Lloveras E, Vila RM, Besses C, Montserrat E, Sans-Sabrafen J. Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma. Cancer Genet Cytogenet 1999; 111:92-8.
  • Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158: 1889-93
  • López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM, González M, Ribera JM, Brunet S, García-Conde J, Fernández de Sevilla A, Bosch F, Montserrat E. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol 1998; 9: 849-55.
  • Sanz L, López-Guillermo A, Martínez C, Bosch F, Esteve J, Cobo F, Montoto S, Perales M, Bladé J, Cervantes F, Campo E, Montserrat E. Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. Eur J Haematol 1998; 61: 59-64.
  • Terol MJ, López-Guillermo A, Bosch F, Villamor N, Cid MC, Rozman C, Campo E, Montserrat E. Expression of the adhesion  molecule ICAM-1 (CD54) in non-Hodgkin’s lymphoma. Relationship with tumor dissemination and prognostic importance. J Clin Oncol 1998; 16: 35-40.
  • Targarona EM, Espert JJ, Balague C, Sugranes G, Ayuso C, Lomena F, Bosch F, Trias M. Residual splenic function after laparoscopic splenectomy: a clinical concern. Arch  Surg 1998; 133:56-60.
  • Montserrat E, Bosch F, Rozman C. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Ann Oncol. 1997;8 1:93-101
  • Montserrat E, Bosch F, Rozman C. Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectivas. J Intern Med 242: 63-67 740, 1997
  • Bosch F, López-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, Vallespi T, Woessner S, Montserrat E. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567-75.
  • Esteve J, Villamor N, Colomer D, Bosch F, López-Guillermo A, Rovira M, Urbano-Ispizua A, Sierra J, Carreras E, Montserrat E. Hematopoietic stem-cell transplantation for chronic lymphocytic leukemia. Report of 12 patients from a single institution. Ann Oncol 1998; 9: 167-72.
  • Rozman C, Bosch F, Montserrat E Chronic lymphocytic leukemia: a changing natural history? Leukemia. 1997 Jun;11(6):775-8.
  • Cervantes F, López-Guillermo A, Bosch F, Terol MJ, Rozman C, Montserrat E. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol 1996; 57: 286-91.
  • Briones J, Montserrat E, Urbano-Ispizua A, Esteve J, Colomer D, López-Guillermo A, Bosch F, Hadjieu E, Rozman C. Tratamiento con fludarabina de neoplasias linfoides de bajo grado de malignidad resistenctes al tratamiento o en recaída. Med Clin 1996; 107: 86-9.
  • Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernández PL, Sánchez-Beato M, Soler F, Pérez-Losada A, Nayach I, Mallofré C, Piris MA, Montserrat E, Cardesa A. Expression of retinoblastoma gene product (pRb) in mantle cell lymphoma. Correlation with Cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol, 1996; 148(5): 1591-1600.
  • Montserrat E, López-Lorenzo JL, Manso F, Martín A, Prieto E, Arias-Sampedro J, Fernández MN, Oyarzábal FJ, Odriozola J, Alcalà A, García-Conde J, Conde E, Guardia R, Bosch F. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia. The Spanish Group Experience. Leukemia and Lymphoma, 1996; 21:467-472.
  • Montserrat E, Villamor N, Reverter JC, Brugues RM, Tassies D, Bosch F, Aguilar JL, Vives-Corrons JL, Rozman M, Rozman C. Bone marrow assessment in B-cell chronic lymphocytic leukemia: aspirate or biopsy?. A comparative study in 258 patients. Br J Haematol, 1996; 93(1): 111-116.
  • Hernández L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffold M. p53 gene mutations and protein overexpression are associated with agressive variants of mantle cell lymphomas. Blood, 1996; 87(8): 3351-3359.
  • Esteve J, Cervantes F, Bosch F, Cobo F, Montserrat E, Rozman C. Tratamiento con interferón alfa del síndrome hipereosinofílico idiopático resistente a la terapéutica convencional. Med Clin, 1996; 106: 304-306.
  • Montserrat E, Bosch F, López-Guillermo A, Graus F, Terol MJ, Campo E, Rozman C. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996; 14: 941-4.
  • Bosch F, Campo E, Jares P, Pittaluga S, Muñoz J, Nayach I, Piris MA, DeWolf-Peeters C, Jaffe ES, Rozman C, Montserrat E, Cardesa A. Increased expression of the PRAD-1/CYCLIN D1 gene in hairy cell leukemia. Br J Haematol 1995; 91(4): 1025-1030.
  • Esteve J, López-Guillermo A, Martínez-Francés A, Bosch F, Terol MJ, Campo E, Montserrat E, Rozman C. Presenting features, natural history, and prognostic factors in localized non-Hodgkin’s lymphomas: analysis of 117 cases from a single institution. Eur J Haematol 1995; 55: 217-222.
  • Fraga M, Lloret E, Sánchez-Verde L, Orrade JL, Campo E, Bosch F, Piris MA. Mucosal mantle (centrocytic) lymphomas. Histopathology, 1995; 26: 413-422.
  • Martínez – Francés A; López – Guillermo A; Esteve J; Bosch F; Terol MJ; Montserrat E. Characteristics of patients with low grade malignant lymphoma and long survival. Sangre (Barc). 1995 Feb;40(1):53-7.
  • Bosch F, Jares P, Campo E, López-Guillermo A, Villamor N, Tassies D, Piris MA, Jaffe ES, Montserrat E, Rozman C, Cardesa A. PRAD-1/Cyclin D1 overexpression in lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994; 84(8): 2726-2732.
  • Bladé J, López-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C. Impact of response to treatment on survival in multiple myeloma: results in a  series of 243 patients. Br J Haematol 1994; 88: 117-21.
  • López-Guillermo A, Montserrat E, Bosch F, Escoda L, Terol MJ, Marín P, Reverter JC, Bladé J, Cervantes F, Sierra J, Rovira M, Nomdedeu B, Urbano-Ispizua A, Carreras E, Campo E, Rozman C. Low-grade lymphomas: clinical and prognostic studies in a series of 143 patients from a single institution.Leuk Lymph 1994; 15: 159-65.
  • Jares P, Fernández PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J, Cardesa A. PRAD1/Cyclin D1 gene amplification correlates with mRNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 1994; 54: 4813-4817.
  • López-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343-8.
  • Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, Vives J, Cardesa A, Yagüe J. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorrectal carcinomas. Cancer 1994; 73: 2913-2921.
  • Villamor N, Marín P, Aymerich M, Arriols R, Rovira M, Bosch F, Vilella R, Rozman C, Vives-Corrons JL. Diagnóstico de la hemoglobinuria paroxística nocturna mediante el análisis citofluorimétrico de moléculas unidas a membrana por grupos glucosilfosfatidilinositol. Med Clin 1994; 102: 481-484.
  • Cervantes F, Urbano-Ispízua A, Pujades A, Bosch F, Vives-Corrons JL, Montserrat E, Rozman C. Análisis molecular en la leucemia mieloide crónica cromosoma Filadelfia negativa: estudio de seis casos.Med Clin 1992; 99: 286-288
  • Sierra J, Grañena A, Bosch F, Carreras E, Martí JM, Urbano-Ispízua A, Rovira M, Rozman C. Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: response to treatment and factors influencing outcome. Hematol Oncol 1992; 10: 301-309.